Trial reportBMC cancer2013
Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy.
Trial report in BMC cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 83 citations in OpenAlex.
- Do histological variants in urothelial carcinoma of the bladder portend poor prognosis? A systematic review and meta-analysis.Oncotarget · 2017Pooled it
- Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma.British journal of cancer · 2021Trial
- A case of Avelumab response to multiple bone and lymph node metastases of plasmacytoid variant bladder cancer.Urology case reports · 2023Article
- Urothelial Carcinoma: Divergent Differentiation and Morphologic Subtypes.Surgical pathology clinics · 2022Review
- Plasmacytoid variant urothelial carcinoma of the bladder: effect of radical cystectomy and chemotherapy in non-metastatic and metastatic patients.World journal of urology · 2022Article
- Overview of histologic variants of urothelial carcinoma: current trends and narrative review on treatment outcomes.Translational andrology and urology · 2022Review
- Outcomes of poorly differentiated and plasmacytoid variant bladder urothelial carcinoma.BJUI compass · 2022Article
- Plasmacytoid Urothelial Carcinoma of the Bladder That Manifests Disseminated Carcinomatosis of the Bone Marrow: A Case Report of Extremely Rapid Progression.Case reports in urology · 2022Article
- Histologically confirmed distant metastatic urothelial carcinoma from the urinary bladder: a retrospective review of one institution's 20-year experience.Journal of pathology and translational medicine · 2021Article
- A case report of a patient with plasmacytoid urothelial cancer with significant response to HER2-targeting therapy and enfortumab vedotin.American journal of clinical and experimental urology · 2021Article
- The optimal management of variant histology in muscle invasive bladder cancer.Translational andrology and urology · 2020Review
- Metastatic Plasmacytoid Bladder Cancer Harboring a CDH-1 Mutation and Producing High Levels of CA 19-9. A Case Report and Literature Review.The American journal of case reports · 2020Review
- Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations.Human pathology · 2019Article
- The Impact of Plasmacytoid Variant Histology on the Survival of Patients with Urothelial Carcinoma of Bladder after Radical Cystectomy.European urology focus · 2019Article
- Plasmacytoid Urothelial Carcinoma of Ureter with Retroperitoneal Metastasis: A Case Report.The American journal of case reports · 2018Review
- Advances in risk stratification of bladder cancer to guide personalized medicine.F1000Research · 2018Review
- Characteristics and clinical significance of histological variants of bladder cancer.Nature reviews. Urology · 2017Review
- Urothelial carcinoma in first histological diagnosis of patients over 80 years has distinctive histological features: a retrospective single-institution study of 185 patients.Virchows Archiv : an international journal of pathology · 2017Article
- Plasmacytoid Urothelial Carcinoma of the Urinary Bladder Metastatic to the Duodenum: A Case Report-Diagnostic Relevance of GATA3 Immunohistochemistry.Case reports in pathology · 2017Article
- Variant histology in bladder cancer: how it should change the management in non-muscle invasive and muscle invasive disease?Translational andrology and urology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSince the definition of different histologic subtypes of urothelial carcinomas by the World Health Organization (WHO) 2004 classification, description of molecular features and clinical behavior of these variants has gained more attention.
methodsWe reviewed 205 tumor samples of patients with locally advanced bladder cancer mainly treated within the randomized AUO-AB05/95 trial with radical cystectomy and adjuvant cisplatin-based chemotherapy for histologic subtypes. 178 UC, 18 plasmacytoid (PUC) and 9 micropapillary (MPC) carcinomas of the bladder were identified. Kaplan Meier analysis and backward multivariate Cox's proportional hazards regression analysis were performed to compare overall survival between the three histologic subtypes.
resultsPatients suffering from PUC have the worst clinical outcome regarding overall survival compared to conventional UC and MPC of the bladder that in turn seem have to best clinical outcome (27.4 months, 62.6 months, and 64.2 months, respectively; p=0.013 by Kaplan Meier analysis). Backward multivariate Cox´s proportional hazards regression analysis (adjusted to relevant clinicopathological parameters) showed a hazard ratio of 3.2 (p=0.045) for PUC in contrast to patients suffering from MPC.
conclusionsHistopathological diagnosis of rare variants of urothelial carcinoma can identify patients with poor prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.